The medical community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s exhibiting significant efficacy in clinical trials for managing obesity. Unlike some existing weight loss solutions, retatrutide appears to offer a more substantial decrease in body mass and improve metabolic health, particularly